This Doctolib company profile covers the company's valuation, revenue, funding rounds, investors and history. Doctolib works in health technology, with a focus on appointment booking and practice software. It was founded in 2013 and is headquartered in Paris, France. Its latest valuation on record is €5.8 billion (last primary round) (March 2022). Every figure links to a public source, and anything the company hasn't disclosed is marked as such.
Revenue
About €348 million ARR, up 22.5% — Annual recurring revenue, 2024 (company figures reported by Les Echos and Sifted), as of 2024. Source: Sifted.
| Metric | Value | As of | Source |
|---|---|---|---|
| Adjusted EBITDA loss | €53.8 million, down 38% from €87.1 million | 2024 | Sifted |
| R&D spending | €115 million, about a third of revenue | 2024 | Sifted |
Funding history
| Date | Round | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Mar 2022 | Series F (equity and debt) | €500M | €5.8B | Eurazeo (lead); Bpifrance, General Atlantic | Tech.eu |
Doctolib timeline
Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.
- 2013 — Doctolib is founded in Paris by Stanislas Niox-Chateau (CEO), Ivan Schneider, Jessy Bernal and Steve Abou Rjeily.
- Mar 2022 — Series F (equity and debt): €500M, valuing the company at €5.8B. Investors: Eurazeo (lead); Bpifrance, General Atlantic.
- 2024 — Adjusted EBITDA loss: €53.8 million, down 38% from €87.1 million.
- 2024 — R&D spending: €115 million, about a third of revenue.
Investors
Overview
Doctolib runs Europe's best-known platform for booking medical appointments, used by tens of millions of patients in France, Germany and Italy. Patients search for doctors, dentists and other health professionals, see available times and book online. For practitioners, Doctolib sells software that manages their calendar, sends reminders, handles video consultations, and increasingly runs the whole practice, from patient records to AI tools that help with paperwork.
Stanislas Niox-Chateau, the CEO, founded Doctolib in Paris in 2013 with Ivan Schneider, Jessy Bernal and Steve Abou Rjeily. It became France's most valuable startup in 2022 and gained wide public recognition during the Covid-19 pandemic, when governments in France and Germany used its platform to book vaccination appointments.
How Doctolib makes money
Patients use Doctolib for free. Revenue comes from health professionals and institutions, who pay monthly subscriptions for its software. A doctor's practice pays for scheduling and patient management, while hospitals and clinics pay for larger deployments. Doctolib has added more modules over time, including teleconsultation, secure messaging between practitioners, patient records software and AI assistance, which raise revenue per customer. Subscriptions give it predictable, recurring income.
Revenue and losses
Doctolib published financial figures for the first time for 2024, as reported by Les Echos and Sifted. Annual recurring revenue reached about €348 million, up 22.5%. Germany accounted for a growing share, reported at roughly a fifth of ARR. The company spent €115 million on research and development, about a third of revenue, and reduced its adjusted EBITDA loss by 38% to €53.8 million. Other reporting put the 2024 net loss higher, so the EBITDA figure shouldn't be read as the bottom line. The company said it expected to become profitable soon; we haven't seen a confirmed profitability announcement.
Funding history
Doctolib raised several large rounds from investors including Eurazeo, Bpifrance and General Atlantic. In March 2022 it raised €500 million in equity and debt at a €5.8 billion valuation, led by Eurazeo, making it France's most valuable startup at the time. It planned to use the money to hire thousands of people across France, Germany and Italy over five years.
Reports in late 2025 described a large secondary sale by employees and early investors at a valuation well below the 2022 figure. We haven't confirmed the terms from a primary source, so the data above uses the 2022 round. A lower secondary price wouldn't change the company's own valuation formally, but it signals how investors value it today. Our guide to down rounds explains the dynamics.
AI and product strategy
Doctolib has invested heavily in AI for practitioners, including an assistant that listens to consultations (with patient consent) and drafts notes, and tools that automate administrative tasks. Reducing paperwork is a major selling point in health systems where doctors are in short supply. The company has also expanded into software for hospitals and into practice management systems, aiming to become the main software platform for healthcare professionals.
Privacy and regulation
Handling health data brings strict regulation and public scrutiny. Doctolib has faced criticism over data hosting and privacy in the past and has invested in encryption, including acquiring encryption specialist Tanker in 2022. It operates under European data protection law and national health data rules. Trust is essential: practitioners and patients must be confident their data is secure.
Competitive landscape
Doctolib competes with national appointment platforms, practice management software vendors, hospital software providers and telehealth services in each market. In Germany it faces established practice software companies. Its advantages are scale, brand recognition among patients, and a broad product suite. Its challenges are that healthcare software is sold country by country under different rules, and that growing beyond booking requires competing with entrenched clinical software providers.
What to watch next
Watch whether Doctolib announces profitability, adoption of its AI assistant, expansion of hospital software, the terms of any secondary sale or new round, and IPO plans.
Key facts at a glance
Doctolib is a Paris health technology company founded in 2013 by Stanislas Niox-Chateau, Ivan Schneider, Jessy Bernal and Steve Abou Rjeily. It reported about €348 million in ARR for 2024, up 22.5%, with an adjusted EBITDA loss of €53.8 million. It raised €500 million at a €5.8 billion valuation in March 2022, led by Eurazeo.
Why healthcare software is sticky
Once a medical practice runs its calendar, patient communications and records through one system, switching is hard. Staff are trained on it, patients know how to book, and data migration is risky. That gives healthcare software companies very loyal customers and steady subscription revenue. The flip side is slow sales cycles and heavy regulation, especially for hospital contracts. Companies that win in healthcare usually grow steadily rather than explosively.
The two-sided platform model
Doctolib is a classic two-sided platform: patients on one side, health professionals on the other. Each side makes the platform more valuable for the other. The more doctors list their availability on Doctolib, the more useful it becomes for patients, and the more patients book through it, the more attractive it is for doctors to join. Once a platform reaches that point in a city or country, it becomes very hard for rivals to catch up. Doctolib's strategy has been to reach that density country by country, starting in France and then Germany and Italy.
The model also creates a responsibility. When a single platform handles a large share of medical bookings, regulators and the public expect high standards of reliability, fairness and data protection. Doctolib's growth into practice software and AI deepens its role in the healthcare system, which increases both its value and the scrutiny it faces.
Questions to ask before choosing practice software
- Does it integrate with your existing patient records and billing systems?
- Where is health data hosted, and what certifications does the provider hold?
- What does onboarding and staff training involve?
What this means if you're…
A healthcare practice: compare booking and practice software on integration with your records system, data security and total subscription cost.
A health tech founder: Doctolib shows the power of a two-sided platform where patients use the service free and practitioners pay.
An investor: watch the gap between the 2022 valuation and current secondary prices alongside its path to profit.
Latest developments (October 2026)
Doctolib has not announced a new primary round since 2022, when it was valued at €5.8 billion, which remains the latest sourced figure. It has continued expanding its AI tools for doctors, including medical assistants that help with documentation, and serves practitioners in France, Germany, Italy and the Netherlands. IPO speculation has continued, but we found no announced plans. See our largest French startups guide.
Sources
Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.
Frequently asked questions
What does Doctolib do?
Doctolib is a health technology / appointment booking and practice software company headquartered in Paris, France. It was founded in 2013.
What is Doctolib's valuation?
Doctolib was valued at €5.8 billion (last primary round) as of March 2022, according to Tech.eu. Private company valuations are set at funding rounds or share sales and can change significantly between them.
How much revenue does Doctolib make?
Doctolib reported About €348 million ARR, up 22.5% (annual recurring revenue, 2024 (company figures reported by les echos and sifted)) as of 2024, according to Sifted.
What was Doctolib's latest funding round?
The most recent financing we have verified is a series f (equity and debt) in Mar 2022: €500M, at a valuation of €5.8B. Source: Tech.eu.
Who are Doctolib's investors?
Investors named in public announcements include Eurazeo, Bpifrance and General Atlantic.
Who founded Doctolib?
Doctolib was founded in 2013 by Stanislas Niox-Chateau (CEO), Ivan Schneider, Jessy Bernal and Steve Abou Rjeily.
Is Doctolib a public company?
No. Doctolib is a private company (private, venture backed), so its shares are not traded on a stock exchange and it isn't required to publish its financial results.
Where is Doctolib headquartered?
Doctolib is headquartered in Paris, France.